Ozempic microdosing: what the trials studied, and what they did not

What people mean by microdosing Ozempic

Microdosing is not a clinical term for GLP-1 medicines. In practice it describes staying at, or below, the starting dose of semaglutide indefinitely instead of titrating up to the maintenance amounts the trials used.

• Ozempic's labeled schedule starts at 0.25 mg once weekly for four weeks. That starting dose exists to let side effects settle — the label states it is not intended for glycemic control.
• Wegovy, the weight-management form of semaglutide, titrates over 16 weeks to 2.4 mg weekly, which is the dose used in the STEP trials.
• So-called microdosing usually means holding at 0.25 mg, or splitting doses smaller still, often from a compounded vial rather than a labeled pen.
• People give three reasons: side effects, cost, and wanting a smaller effect. Those are real motivations; they do not by themselves make the approach studied.

What the trials actually used

The published weight and cardiometabolic results come from specific doses. Knowing them is the only way to judge what a smaller one might or might not do.

• STEP 1: semaglutide 2.4 mg weekly produced a mean body-weight change of about −14.9% at 68 weeks, versus −2.4% with placebo.
• SUSTAIN and the diabetes program used 0.5 mg and 1.0 mg weekly for glycemic control; 2.0 mg was later approved for type 2 diabetes.
• The 0.25 mg starting dose has no efficacy claim attached to it in the labeling at all — it is an escalation step.
• There is no published randomized trial of a maintained sub-therapeutic dose for weight loss, so the size and durability of any effect at 0.25 mg is unstudied rather than established.
• Cardiovascular outcome data (SELECT) also comes from 2.4 mg, not from reduced dosing.

The compounded-vial problem

Most microdosing in practice involves drawing from a compounded vial, and that carries a separate set of risks from the dosing question.

• The FDA has warned about dosing errors with compounded semaglutide, including patients drawing many times the intended amount when converting between milligrams and units.
• Some compounded products use semaglutide salt forms that are not the active ingredient in the approved medicines.
• Compounded products are not FDA approved and are not reviewed for safety, effectiveness or quality before marketing.
• Dose-splitting from a vial adds arithmetic where a pen has none. Write the concentration down; do not do the conversion in your head.

Tracking a GLP-1 dose honestly

Whatever dose you and your prescriber settle on, the record is what makes the next decision better than the last one.

• Log the dose in mg and, for a vial, the volume drawn in units — both, every time.
• Record the injection day and site; weekly medicines drift without a fixed anchor.
• Track weight, appetite and side effects on the same timeline, so a dose change has a visible before and after.
• Note titration decisions and who made them, so a clinic visit starts with facts rather than recollection.
• Check interactions, particularly with insulin or sulfonylureas, where dose adjustments may be needed.

References

• STEP 1: Once-weekly semaglutide 2.4 mg in adults with overweight or obesity (NEJM)
• FDA prescribing information — Ozempic (semaglutide) dosing and administration
• FDA — Medications containing semaglutide marketed for type 2 diabetes or weight loss
• SELECT: Semaglutide and cardiovascular outcomes in obesity without diabetes (NEJM)